HistoIndex and CymaBay Therapeutics Team Up to Advance NASH Drug Development

HistoIndex and CymaBay Therapeutics Team up to Advance NASH Drug Development   Histoindex Pte. Ltd., with the world’s first stain-free Genesis®200 multiphoton digital pathology system, is collaborating with CymaBay Therapeutics, Inc. to evaluate the efficacy of seladelpar in a randomized, double-blind, placebo-controlled, multi-center Phase 2b study of 175 subjects with biopsy-confirmed Nonalcoholic Steatohepatitis (NASH). Genesis®200’s novel imaging technology encompasses …

HistoIndex and CymaBay Therapeutics Team Up to Advance NASH Drug Development Read More »